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Abstract
Deregulation of DNA repair enzymes occurs in cancers and may create a susceptibility to chemotherapy. Expression
levels of DNA repair enzymes have been shown to predict the responsiveness of cancers to certain chemotherapeutic
agents. The RECQ helicases repair damaged DNA including damage caused by topoisomerase I inhibitors, such
as irinotecan. Altered expression levels of these enzymes in colorectal cancer (CRC) may influence the response of
the cancers to irinotecan. Thus, we assessed RECQ helicase (WRN, BLM, RECQL, RECQL4, and RECQL5) expres-
sion in primary CRCs, matched normal colon, and CRC cell lines. We found that BLM and RECQL4 mRNA levels are
significantly increased in CRC (P = .0011 and P< .0001, respectively), whereas RECQL and RECQL5 are significantly
decreased (P = .0103 and P = .0029, respectively). RECQ helicase expression patterns varied between specific
molecular subtypes of CRCs. The mRNA and protein expression of the majority of the RECQ helicases was closely
correlated, suggesting that altered mRNA expression is the predominant mechanism for deregulated RECQ helicase
expression. Immunohistochemistry localized the RECQ helicases to the nucleus. RECQ helicase expression is
altered in CRC, suggesting that RECQ helicase expression has potential to identify CRCs that are susceptible to
specific chemotherapeutic agents.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer deaths in the
United States, affecting more than 140,000 people annually [1]. The
majority of people with CRC are diagnosed with advanced stage disease
that will require adjuvant chemotherapy in addition to surgical resec-
tion of the primary cancer [2]. Currently, pathologic stage is the best
prognostic factor available and is used to identify patients who are most
likely to benefit from adjuvant chemotherapy and/or radiation therapy
[3]. Although pathologic stage is the best predictive indicator for de-
termining response to adjuvant therapy, 30% to 40% of presumably
cured patients develop recurrent disease [3]. Therefore, there is a need
for markers that more accurately identify patients who would benefit
from more aggressive adjuvant therapy and for markers that identify
the most effective agents for treating a specific patient’s cancer.
Molecular alterations in CRC, such as altered gene expression
levels, have the potential to be more accurate than pathologic stage
for predicting response to treatment. Molecular alterations are likely
more accurate predictive markers than TNM stage, because they
often directly affect biologic processes that mediate the manner in
which cancer cells respond to specific chemotherapeutic agents.
These alterations often affect processes central to the mechanisms
of action of chemotherapeutic agents, such as the regulation of
DNA repair and genomic stability, thereby affecting the cancer’s
response to chemotherapy [4,5].
Genomic instability is one of the hallmarks of cancer and results
from the loss of the ability to maintain the integrity of the genome.
Loss of genomic stability results in increased mutation rates in cancer
cells and appears to play a prominent role in the response of cancers
to chemotherapy [4,6]. DNA damage, if left unrepaired, contributes
to genomic instability. DNA damage occurs on a regular basis in cells
as a consequence of exposure to environmental mutagens and cellular
metabolites. The integrity of the genome is normally maintained by
DNA repair enzymes, which can be grouped into functional categories
depending on the type of DNA damage they repair. Their dysfunction
can contribute to altered DNA processing, genomic instability, and
increased susceptibility to aberrant genetic alterations [7,8]. Impor-
tantly, recent in vitro studies have shown that cancers with loss of
function of DNA repair enzymes have an increased susceptibility to
chemotherapeutic agents that induce the type of damage normally
repaired by those enzymes [7,9]. These studies as well as the successful
proof-of-principle studies involving poly (ADP-ribose) polymerase
(PARP) inhibitors in BRCA1-deficient tumors [10,11] have led to an
intense investigation of DNA repair enzymes as biomarkers in cancers.
From a clinical vantage, the altered expression of DNA repair
enzymes has the potential to be used for predicting the response of a
cancer to specific chemotherapeutic agents. The differential response
of CRCs to DNA-damaging chemotherapeutic agents may reflect the
specific DNA repair capabilities of the cancers. Studies have shown
that the currently recognized molecular subtypes of CRC can have
different clinical behaviors with regard to treatment outcomes. CRCs
demonstrating microsatellite instability (MSI) secondary to DNA mis-
match repair deficiency have reduced response to 5-fluorouracil [12,13],
whereas this same subtype may be more responsive to irinotecan-
containing regimens [14]. It is not yet fully understood what drives this
variability in clinical response to chemotherapy; however, it is likely
rooted in the molecular heterogeneity of each cancer. The variability
in clinical response to DNA-damaging chemotherapeutic agents may
be driven by heterogeneity in the expression or function of key DNA
repair enzymes.
The RECQ helicases are a family of DNA repair enzymes that
unwind double-stranded nucleic acids and have a central role in main-
taining genomic integrity [15]. The RECQ helicase family includes
five ATP-dependent enzymes (WRN, BLM, RECQL, RECQL4,
and RECQL5) that have a conserved 3′ to 5′ helicase domain and
two additional conserved regions, the RQC and HRDC regions
[15]. They modulate complexes involved in homologous recombina-
tion, replication fork migration, translocation, and the structure and
function of nucleoprotein filaments. They also process topoisomerase
I–mediated DNA damage induced by camptothecin derivatives, such
as irinotecan [16]. Autosomal recessive loss of function of three of
these DNA-modulating enzymes, WRN, BLM and RECQL4, results
in human syndromes characterized by constitutional genomic instabil-
ity and premature aging [17]. These syndromes have also been linked
to increased cancer susceptibility, including CRC, making the func-
tion of these helicases a point of interest in the pathogenesis of CRC.
Furthermore, deficiencies in RECQ helicases have also been shown to
result in a cancer-prone phenotype in mice [18,19].
Because the RECQ helicases play a significant role in the main-
tenance of genomic stability and DNA repair, altered expression of
the RECQ helicases may play a role in the pathogenesis of CRC.
Furthermore, RECQ helicase expression may be useful for iden-
tifying CRCs that are susceptible to specific DNA-damaging chemo-
therapeutic agents, including those drugs commonly used for the
treatment of CRC, 5-fluorouracil, oxaliplatin, and irinotecan [20–
22]. Both WRN- and BLM-depleted cells have impaired survival
after treatment with the DNA-damaging agents cisplatinum and
5-fluorouracil as well as camptothecin [23]. RECQL5-deficient cell
lines show increased sensitivity to camptothecin [20]. Overexpression
of one or more of these helicases may mediate resistance to DNA-
damaging chemotherapeutic agents, whereas underexpression may
identify cancers that are particularly susceptible to these agents. We
hypothesized that the expression of the RECQ helicases would dif-
fer in primary CRCs compared to matched normal colonic mucosa.
Furthermore, we also hypothesized that the expression of the RECQ
helicases may differ among the molecular subtypes of CRC. We
used quantitative reverse transcription–polymerase chain reaction
(qRT-PCR) as well as Western blot analysis and immunohisto-
chemistry (IHC) to assess our hypothesis and found that BLM and
RECQL4 expression are increased in CRC, whereas RECQL and
RECQL5 expression are decreased. We also show that there are char-
acteristic RECQ helicase expression patterns for different molecular
subtypes of CRC. The RECQ helicases are plausible candidates for
the development of biomarkers that may predict the therapeutic
response of CRCs to chemotherapeutic agents and may be important
in CRC pathogenesis.
Materials and Methods
CRC Cases
A total of 46 sporadic primary CRC cases with matched normal
colon was assayed. Twenty-six primary CRC cases with matched nor-
mal colon tissue were obtained from the Cooperative Human Tissue
Network (CHTN) as fresh frozen tissue. An additional 20 primary
CRC cases with matched normal colon tissue were obtained in the
form of first-strand cDNA (TissueScan Colon Cancer Tissue qPCR
Panel III) from OriGene (Rockville, MD). All cases were composed
of >60% tumor epithelium.
Translational Oncology Vol. 6, No. 4, 2013 Altered RECQ Helicase Expression Lao et al. 459
Human CRC Tissue Microarrays
CRC tissue microarrays (TMAs) were purchased from OriGene
(Catalog No. CT565900). TMAs contained 50 × 1 mm cores from
formalin-fixed paraffin-embedded (FFPE) samples (40 tumors and
10 normal tissues). Data for individual cases including age, gender,
pathology, grade, stage, and so on can be found at http://www.origene.
com/Tissue/getTissueMicroArray.aspx?id=TMA002.
Quantitative Real-Time PCR
RNA extraction from fresh frozen tissue was conducted using
TRIzol as recommended by the manufacturer, followed by purification
using the RNeasyKit (Qiagen, Foster City, CA). cDNAwasmade using
SuperScript II Reverse Transcriptase (Invitrogen, Grand Island, NY),
1× PCR buffer, MgCl2 (8 mM), RNase out, and 1 to 4 μg of the
appropriate total RNA. Real-time quantitative PCR assays were
conducted using TaqMan probe and primers (Applied Biosystems,
Grand Island, NY) for WRN (Hs00172155_m1), BLM (Hs00172060_m1),
RecQL (Hs00262956_m1), RecQL4 (Hs00171627_m1), RecQL5
(Hs00188633_m1), GusB (Hs99999908_m1), and PCNA
(Hs00427214_g1) along with TaqMan Universal PCR Mix (Applied
Biosystems) as recommended by the manufacturer. GUSB expression
was used as a loading control, and PCNA expression was used to nor-
malize for proliferation [24–28]. The relative standard curve method
was used in determining RECQ helicase expression levels. Control
RNA was obtained from the following CRC cell lines: LS174T for
WRN and RECQL and SW480 for BLM, RECQL4, RECQL5,
and PCNA.
CpG Island Methylator Phenotype Analysis
Genomic DNA extraction from fresh frozen tissue was con-
ducted using the DNeasy Kit (Qiagen) according to the protocol
recommended by the manufacturer. Subsequently, the DNA was
bisulfite converted using the Zymo Research EZ DNA methylation
kit according to the manufacturer’s protocol. CpG island methylator
phenotype (CIMP) analysis was conducted using Methylight assays
according to the protocol published by Weisenberger et al. [29], using
probe primer sets and ALU-based normalization (Table W1).
The percent methylation ratio for each gene was determined for
each tumor sample using the following equation: [(gene × mean value
for sample)/(ALUC4 mean value for sample)]/[(gene × mean value
for the methylated control)/(ALUC4 mean value for the methylated
control)] * 100. A sample is scored as being CIMP positive if
greater than or equal to three of five genes has a percent methylation
ratio of >10.
MSI Analysis
Genomic DNA was extracted from the tissues as described. MSI
status of the CHTN samples was determined from genomic DNA
according to a previously published protocol [30].
RECQ Helicase Expression and Localization Using IHC
TMAs were deparaffinized and rehydrated in distilled water.
Endogenous peroxidase activity was blocked using 0.5% H2O2. The
following antibodies and conditions were used for RECQ IHC. For
WRN IHC, antigen retrieval was performed using heat-induced
epitope retrieval in Epitope Retrieval 2 (Leica Biosystems, Buffalo
Grove, IL). Mouse monoclonal 195C to Werner’s syndrome helicase
(ab62747; Abcam, Cambridge, MA) was diluted 1:100. For BLM IHC,
antigenretrievalwasasdescribedforWRN.Anti-BLMantibodyproduced
inrabbit (HPA005689;Sigma,StLouis,MO)wasdiluted1:100.RECQL
antigen retrievalwas alsoasdescribed forWRN.RECQLrabbitpolyclonal
antibody (sc-25547; Santa Cruz Biotechnology, Dallas, TX) was diluted
1:50. RECQL4 antigen retrieval was performed using heat-induced epi-
tope retrieval in Epitope Retrieval 1 (Leica Biosystems). RECQL4
monoclonal antibody (M09), clone 2G8 (H00009401-M09; Abnova,
Taipei City, Taiwan), was diluted 1:50. RECQL5 antigen retrieval was
performed as described for WRN. Anti-RECQL5 rabbit polyclonal
antibody (Sigma; HPA029971) was diluted 1:150. TMAs were in-
cubated with primary antibody for 20 minutes in a Leica Bond XX.
3,3-Diaminobenzidine substrate was used to visualize RECQ-positive
cells. TMAs were counterstained with hematoxylin. Cores were scored
using the Allred scoring system, which combines two staining categories
(proportion and intensity) to yield a single numerical score [31]. The
Allred score ranges from 0 to 8. It is arrived upon by the addition of two
scores, a proportion score and an intensity score, to reflect both the
number of tumor cells stained as well as how strongly they stain.
The proportion score ranges from 0 to 5 (0 = no cells stained, 1 =
1/100 cells stained, 2 = 1/10 cells stained, 3 = 1/3 cells stained, 4 =
2/3 cells stained, 5 = all cells stained), and an intensity score ranges from
0 to 3 (0 = negative, 1 = weak, 2 = intermediate, 3 = strong). Any non-
epithelial cells that stained with the antibodies used were not included
in this assessment.
Protein Expression Using Western Blot
Cell lysates were prepared in RIPA buffer, and the proteins were
resolved using 12% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE), then transferred to polyvinylidene difluoride
(PVDF) membranes and subsequently blocked in 5% non-fat dry milk
in tris-buffered saline with Tween 20 (TBST). The membranes were
incubated overnight with individual primary antibodies diluted 1:1000
at 4°C and then incubated for 1 hour with secondary HRP-conjugated
antibodies diluted 1:5000. β-Actin was used as a protein loading
control. The following antibodies were used for Western blot analysis
experiments:WRN—clone 195C (Sigma); BLM—HPA005689 (Sigma);
RECQL—A1107 (Santa Cruz Biotechnology); RECQL4—2814 (Cell
Signaling Technology, Danvers,MA); RECQL5—HPA029971 (Sigma);
PCNA—sc-7907 (Santa Cruz Biotechnology); β-actin—sc-1616
(Santa Cruz Biotechnology).
Methylation-specific PCR
Genomic DNA was extracted and bisulfite converted, and
methylation-specific PCR was conducted as previously described [32].
The primer sequences used are given as follows: RECQLmethyl-specific
forward primer, 5′-GCGGTCCCAAAAGGGTCAGTTCGGATA-
TCGGATAGTTAAATATCG-3′; RECQL methyl-specific reverse
primer, 5′-GCGGTCCCAAAAGGGTCAGTCCGATCAACAAA-
CGAACGTA-3′; RECQL non–methyl-specific forward primer,
5′-GCGGTCCCAAAAGGGTCAGTTGGATATTGGATAGTTAA-
ATATTGG-3′; RECQL non–methyl-specific reverse primer, 5′-GCG-
GTCCCAAAAGGGTCAGTAAAAACCAATCAACAAACAAACA-
TA-3′; RECQL5 methyl-specific forward primer, 5′-AATTAAAGGT-
TGTTGGTTGGTTTC-3′; RECQL5 methyl-specific reverse primer,
5′-ACTACGCGACGAATATAAAATTACG-3′; RECQL5 non–
methyl-specific forward primer, 5′-AATTAAAGGTTGTTGG-
TTGGTTTT-3; RECQL5 non–methyl-specific reverse primer,
5′-CTACACAACAAATATAAAATTACATA-3′.
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The methylation-specific PCR products were visualized using
electrophoresis on a 1.5% agarose gel with ethidium bromide staining
with subsequent UV transillumination using an Eagle Eye Imaging
System (Stratagene, La Jolla, CA).
Statistical Analysis
As the fold change of RECQ helicase mRNA expression in tumor
compared to the matched normal mucosa was determined to be non-
Gaussian (KS normality and the D’Agostino and Pearson omnibus
normality tests), the significance of the fold change in expression was
determined using the Wilcoxon signed rank test with a theoretical
median of 1. All subsequent analyses were conducted using non-
parametric tests. When comparing the fold change expression of
the RECQ helicases in CRC tumor to the normal colonic mucosa,
a Wilcoxon signed rank test was used. Subgroup analyses of the expres-
sion of each RECQ helicase by stage were conducted using the Kruskal-
Wallis test, with subsequent all-pairwise post-hoc comparisons using
Mann-Whitney tests. Analysis of RECQ helicase expression by early
versus advanced stage (stage I/II vs stage III/IV) was conducted
using the Mann-Whitney test. Mann-Whitney and Wilcoxon signed
rank tests were used to determined the statistical significance in the
IHC studies as well as mRNA expression studies in CRC cell lines
compared to normal colonic mucosa. All statistical tests performed
were two-tailed analyses.
The fold change of RECQL5 expression was used to divide the
tumor samples into two groups, those that have higher RECQL5
expression in normal mucosa compared to tumor and those that have
higher RECQL5 expression in tumor compared to normal mucosa.
Subsequently, the expression of the other RECQ helicases were
analyzed in each of the two groups and their means compared using
a Mann-Whitney test. This analysis was also conducted using the
expression level of each of the RECQ helicases.
Results
Primary CRCs Have Significantly Altered Expression of
RECQ Helicases
We assessed the expression of the five RECQ helicase family
members in sporadic primary human CRC samples and the matched
normal colon tissue. The expression of some members of the RECQ
helicase family has been shown to vary throughout the cell cycle with
the highest expression observed predominantly during S-phase
[24,25]. As we were concerned that alterations in RECQ helicase
expression in specific tumors could be a surrogate marker for prolif-
eration rather than a cell cycle–independent occurrence in the tumor,
we normalized the RECQ helicase mRNA expression data for prolif-
eration using the expression levels of PCNA. PCNA, a cell cycle–
dependent protein that accumulates in the nucleus during S-phase,
can be used to normalize differences that are secondary to prolifera-
tion rates rather than basal expression [26–28]. The data without
normalization for proliferation are shown in Figure W1.
Our results show that, as a group, the primary CRCs display signifi-
cantly higher BLM and RECQL4 mRNA expression levels compared
to normal colonic mucosa (P < .05; Figure 1). In contrast, RECQL
and RECQL5mRNA expression are lower in primary tumors compared
to normal colonicmucosa (P < .05). There was also a significant decrease
in WRN expression between the CRCs compared to the normal colon
(Figure 1). In normal colon, expression of the RECQhelicases showed a
similar degree of inter-case variability to that seen in the cancers
(Figure 1). Receiver operating characteristic (ROC) analysis also showed
non-identity between the expression of WRN, RECQL, RECQL4, and
RECQL5 in tumor versus normal colonic mucosa (Figure W2).
When we compared the fold change of RECQ expression in tumor
versus normal colonic mucosa matched pairs, we observed a signifi-
cantly higher level of expression of BLM and RECQL4 compared to
Figure 1. Expression of RECQ helicase mRNA in primary CRCs and normal colonic epithelium. The primary CRCs have higher BLM
(P = .0049) and RECQL4 (P = .0002) expression compared to normal colonic mucosa, whereas there is lower expression of RECQL
(P = .0046), RECQL5 (P = .0004), and WRN (P = .0049) in primary tumors compared to normal colonic mucosa. Asterisks indicate
statistical significance between the two groups identified.
Translational Oncology Vol. 6, No. 4, 2013 Altered RECQ Helicase Expression Lao et al. 461
the normal mucosa (Figure 2). We also found a significantly lower
level of expression of RECQL and RECQL5 in the CRCs compared to
matched normal mucosa (Figure 2). The tumor/normal ratios of ex-
pression are given as follows: WRN median = 0.5876, mean = 0.8627,
SD = 0.7267 (P = .0881); BLM median = 1.303, mean = 1.795, SD =
1.836 (P = .0011); RECQL median = 0.6496, mean = 0.7973,
SD = 0.568 (P = .0103); RECQL4 median = 1.694, mean =
3.604, SD = 7.878 (P < .0001); RECQL5 median = 0.4731, mean =
1.015, SD = 2.036 (P = .0029; Figure 2).
Furthermore, we observed substantial heterogeneity in the expres-
sion of BLM and RECQL4 in the primary CRCs. The expression
varied by 10-fold (BLM) and 50-fold (RECQL4) between CRCs
(Figure 2). Our results, before normalization for proliferation, are
consistent with data available on RECQ helicase expression in the
Oncomine database (for RECQ helicase mRNA expression in CRC
versus normal colonic tissue), showing an increase in the expression
of all RECQ helicases. Of interest, after normalization for prolifera-
tion, we found a decrease in WRN and RECQL5 expression in tumor
compared to normal mucosa.
We next assessed the CRCs for correlation of expression among
the RECQ helicases in CRC. We found that 3 of 46 (6.5%) cases
had increased expression of all the RECQ helicases, whereas 4 of 46
(8.7%) cases had decreased expression of all five RECQ helicases
compared to the respective matched normal colonic mucosa; however,
this did not correlate with stage.
Characteristic Expression of RECQ Helicases in CIMP and
MSI Subtypes of CRC
We also assessed RECQ helicase expression in the convention-
ally accepted CRC molecular subtypes (MSI and CIMP). We cor-
related RECQ expression level with the CIMP status of the tumors
(CHTN, N = 26) and found that CIMP-positive tumors had
high levels of BLM expression (tumor > normal) compared to non-
CIMP tumors (Table 1). The percentage of BLM high tumors that
displayed CIMP was 26.6%, which is greater than expected by
chance. These data suggest that increased BLM expression in CRC
may be correlated with CIMP-positive tumor status. There was
no correlation between CIMP status and expression of any other
RECQ helicase.
When we analyzed RECQ helicase expression level and MSI status
of the primary sporadic tumors, we found that MSI CRCs (CHTN,
N = 26) had lower RECQL5 and RECQL expression than the matched
normal colonic tissue (Table 2). There was no correlation between MSI
status and expression of any other RECQ helicase. There was no
statistically significant difference in the expression of any of the RECQ
helicases between MSI and microsatellite stable (MSS) tumors.
Comparison of CRCs that Express High Levels of
RECQ Helicases versus CRCs that Express Low
Levels of RECQ Helicases
It has been shown in vitro that certain members of the RECQ
helicase family can interact during DNA repair. Thus, we conducted
an analysis of RECQ helicase expression in CRCs by dividing tumors
into the following two groups: 1) those CRCs with RECQ helicase
expression greater than normal mucosa and 2) those CRCs with
RECQ helicase expression less than normal mucosa. This was done
to determine if distinct populations of CRCs with high or low
expression of the RECQ helicases could be identified on the basis
of expression of any one of the RECQ helicases. To determine if
we could identify an association in the expression level of specific
RECQ helicases, we assessed the correlation between the expression
of RECQ helicases in a pairwise fashion.
We found that grouping cases by the expression level of RECQL5
as either high (tumor > normal) or low expression (tumor < normal)
allowed us to predict similarly high or low expression levels of WRN
and RECQL. Grouping of cases by RECQL5 high or low expression
Figure 2. Fold change of RECQ helicase mRNA expression (CRC/
normal colon). Solid horizontal lines indicate the median fold
change for each RECQ helicase. The dashed horizontal line indi-
cates a fold change level of 1,where the expression level of theRECQ
helicase in the tumor isequal to theexpression level in normal colonic
mucosa. BLM and RECQL4 expression is significantly higher in the
CRCs compared to the matched normal colon (P = .0011 and P <
.0001, respectively). RECQL (P = .0103) and RECQL5 (P = .0029)
expression is significantly lower in the primary CRCs compared to
thematched normal colonmucosa. There is no significant difference
in WRN mRNA expression in tumor compared to normal colonic
mucosa. Asterisks indicate statistical significance in the fold change
compared to the theoretical mean of 1 for the indicated helicases.
Table 1. CIMP Status of CRC Corresponds with Increased BLM Expression.
BLM Expression Non-CIMP CIMP Total Cases Percent CIMP Group Mean SD
T < N 11 0 11 0 0.75 0.22
T > N 11 4 15 26.6 2.62 2.59
All cases 22 4 26 15.3
When BLM expression is used to cluster cases into CRCs with BLM expression less in tumor com-
pared to normal and CRCs with BLM expression greater in tumor compared to normal, we identified
two distinct subgroups of CRCs (P < .05). Although clustering of cases by BLM expression does not
predict differences in expression of any of the other four RecQ helicases, it does correlate with CIMP
status. CIMP-positive tumors were observed only in cases where the expression of BLM was greater in
the tumors compared to the normal colon. These results suggest that CIMP CRCs tend to correlate
with higher BLM expression in the tumor compared to matched normal mucosa and not cases where
BLM expression is decreased in the tumor compared to matched normal mucosa.
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identified distinct populations of CRCs with regard to RECQL5,
WRN, and RECQL expression (P < .05; Figure 3). Of the tumors
that expressed RECQL5 < normal mucosa, 88% also had low levels
(T < N) of RECQL expression, and 85% of those tumors had low
levels (T < N) of WRN expression (Figure 3).
We also found that grouping cases by low expression levels of either
RECQL or WRN was able to predict low levels of RECQL5, confirm-
ing the relationship seen when the cases were grouped using RECQL5
expression. Grouping cases by expression of RECQL4, however, did
not predict differences in expression of the other RECQ helicases.
When BLM expression was used to group tumors into high (tumor >
normal) and low (normal < tumor) BLM-expressing groups, we were
not able to predict expression of any of the other RECQ helicases. How-
ever, CIMP-positive cases were only found among the BLM high tumors
and were not found in BLM low tumors (Table 1).
RECQ Expression Analysis by Stage
Subgroup analyses of the mRNA expression of each RECQ
helicase by stage showed a statistically significant difference in the
expression of WRN in the CRCs compared to normal mucosa by
stage (P = .0498), with the highest average value seen in stage II CRCs
(Figure W3). However, after all-pairwise post-hoc comparisons, there
was not enough power to detect differences inWRN expression among
Table 2. MSI Tumors Have Low Expression of RECQL and RECQL5.
Gene Expression MSS MSI Total Cases Percent MSI Group Mean SD
RECQL, T < N 12 6 18 33.3 0.50 0.30
RECQL, T > N 8 0 8 0 1.71 0.45
RECQL5, T < N 11 6 17 35.3 0.38 0.25
RECQL5, T > N 9 0 9 0 2.84 4.09
All cases 20 6 26 23.1
When either RECQL or RECQL5 expression was used to cluster cases into those that expressed the gene
of interest less than the matched normalmucosa or those that expressed the gene more than thematched
normal mucosa, we were able to identify two distinct subgroups (P < .05). MSI CRCs were observed
only in cases where the expression of RECQL and RECQL5 were less in the CRC compared to the
normal colon. These results suggest that MSI cases correlate with low RECQL and RECQL5 expression
in the tumor compared to the matched normal mucosa. MSS, microsatellite stable (MSI negative).
Figure 3. Classifying CRC cases by RECQL5 expression can predict the expression levels of WRN and RECQL. (A) Of the tumors that
expressed RECQL5 < normal mucosa, 88% also had low levels (T < N) of RECQL expression. (B) Of tumors that expressed RECQL5 >
normal mucosa, 85% had low levels (T < N) of WRN expression. (C) Grouping cases by RECQL5 expression T < N or T > N showed
statistical significance in expression of RECQL5, RECQL, and WRN (P < .05).
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the stages. No significant differences in the expression of BLM (P =
.2193), RECQL (P = .5992), RECQL4 (P = .4077), and RECQL5
(P = .3889) among CRC stages I to IV were observed. The significance
of these results is unclear given the low level of expression of WRN in
the colon and the poor correlation of WRN mRNA expression with
WRN protein expression that we have observed (see below).
When we compared the expression levels in localized disease versus
advanced disease (stages I and II vs stages III and IV), there were no
significant differences in RECQ helicase expression (P > .05). As de-
scribed in the next section, the same analysis was conducted using Allred
scores determined from IHC staining of RECQ helicases in archival
CRC cases. The results from the IHC analysis also show no significant
difference in protein expression for any of the RECQ helicases across
stage, WRN (P = .5709), BLM (P = .3644), RECQL4 (P = .5451),
RECQL (P = .1922), or RECQL5 (P = .5604; Figure W3).
Nuclear Localization of RECQ Helicase in Primary
CRC Tumors
IHC studies were conducted to determine the localization of the
RECQ helicases in CRC tumor tissue and normal colonic mucosa.
For all RECQ helicases, IHC analysis consistently localized the
helicases to the nucleus (Figure 4). However, RECQL5 was also
observed in the cytoplasm as well as in the nucleus. Analysis of Allred
scores for each of the RECQ helicases showed decreased expression
of RECQL5 in tumors compared to normal mucosa (P < .05), con-
sistent with the RECQL5 mRNA levels we observed (Figure 4).
WRN IHC revealed an increase in expression in tumors compared
to normal colon mucosa (P < .05), suggesting that protein expression
levels and mRNA expression levels for WRN do not correlate well,
consistent with data obtained from CRC cell lines (Figure 5). The
other RECQ helicases also show statistically significant differences
in expression between tumor and normal tissue (P < .05; Figure 5);
however, given the small differences in the Allred score between
tumor and normal tissue, we believe that this is unlikely to be clinic-
ally significant. When the intensity score component of the Allred
staining score was analyzed separately from the proportion score
component, we saw a significant difference in the reduction of
RECQL staining intensity and a significant increase in RECQL4 pro-
portion of staining in tumor compared to normal mucosa (P = .0226
and P = .0002, respectively), consistent with the results obtained for
RECQL and RECQL4 mRNA expression.
CRC Cell Lines Show Expression of RECQ Helicases
in a Pattern Similar to Primary CRCs
Given the significant alterations in RECQ helicase expression we
observed in primary CRCs, we assessed the expression of RECQ
helicases in a panel of CRC cell lines to determine the feasibility
of using cell lines to study the functional consequences of alterations
in the expression levels of the RECQ helicases. We studied CRC cell
lines derived from the three major molecular subtypes of CRC, MSS
(or CIN) cancers (SW480, V400, V411, AAC1/SB10, and HT29),
MSI cancers (HCT116, LoVo, and LS174T), and CIMP cancers
(RKO, SW48, and FET). Similar to the pattern of RECQ helicase
expression seen in primary CRCs, the cell lines had higher mRNA
expression levels of BLM and RECQL4 than RECQL, RECQL5, and
WRN. This was true regardless of the molecular subgroup of the
CRC cell line. WRN had the lowest average mRNA expression level
of all the RECQ helicase family members (Figure 5A). We observed
low expression of RECQL (P < .001) and significantly high expres-
sion of RECQL4 (P = .017) in CRC cell lines when compared to
normal colonic mucosa (Figure 5B), which is consistent with the
expression levels we observed in the primary CRCs.
We subsequently assessed RECQ helicase protein expression by
immunoblotting protein lysates from these lines (Figure 5C ). We
found that WRN and RECQL5 protein levels correlated poorly with
mRNA levels but that BLM, RECQL, and RECQL4 showed similar
patterns of mRNA and protein expression. Interestingly, we found
considerable variability among the CRC cell lines, even after nor-
malization for proliferation, of both mRNA and protein expression
for BLM and RECQL4. There was up to approximately three-fold
difference in expression levels across cell lines (Figure 5, B and C ).
Promoter Methylation Status of RECQL and RECQL5
To gain further understanding about the decreased expression of
RECQL and RECQL5 seen in CRCs, we assessed the promoter
methylation status of both RECQL and RECQL5 in normal colonic
mucosa as well as CRC tumors. Our results show the absence of
methylation in both the RECQL (N = 0/7) and RECQL5 (N = 0/8)
promoters in normal colonic mucosa. We also found that 14%
of CRCs have an aberrantly methylated RECQL5 promoter (N =
3/21), whereas 0% of CRCs have a methylated RECQL promoter
(N = 0/16). Thus, the aberrant methylation of the promoters of
RECQL and RECL5 does not seem to be a significant mechanism
for silencing the expression of these genes.
Discussion
The RECQ helicases are a family of enzymes that maintain genomic
stability through their function in DNA processing as helicases and
exonucleases. They participate in DNA repair as members of DNA
repair complexes [33]. They have been shown to be involved in
single-strand break and double-strand break repair [34] as well as
in the repair of topoisomerase I–mediated DNA damage induced by
Figure 4. IHC staining shows localization of RECQ helicases in normal colonic mucosa and CRC. All of the RECQ helicases were detected
in the nucleus in both normal colonic mucosa and CRCs. Allred scores for each of the RECQ helicases from IHC of TMAs are also pre-
sented. Low expression of RECQL5 in tumors compared to normal mucosa can be seen (P = .0031, Wilcoxon signed rank test), which
is consistent with the results obtained from the RECQL5 qRT-PCR assays. WRN showed higher expression in tumors compared to normal
colon mucosa (P = .0128, Mann-Whitney), suggesting that immunostaining scores and mRNA expression levels of WRN do not correlate.
The other RECQ helicases also show statistically significant differences in expression between tumor and normal tissue (BLM, P = .0046,
Wilcoxon signed rank test; RECQL, P = .0287, Wilcoxon signed rank test; RECQL4, P = .0103, Wilcoxon signed rank test); however, this
difference likely does not translate to clinical significance. Allred scores for the selected matched tumor normal images chosen to show
localization are given as follows: WRN: N = 7, T = 0; BLM: N = 7.75, T = 7; RECQL: N = 7.25, T = 6; RECQL4: N = 7, T = 8; RECQL5:
N = 6 (cytoplasmic 2), T = 0 (cytoplasmic 2). All images were photographed at ×20. Asterisks indicate statistical significance between the
two groups identified.
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Figure 5. RECQ helicase expression in CRC cell lines. (A) RECQ helicase mRNA expression was assessed in CRC lines representing the
three major molecular subtypes of CRC, MSS (or CIN) cancers (SW480, V400, V411, AAC1/SB10, and HT29), microsatellite unstable
(MSI) cancers (HCT116, LoVo, and LS174T), and CIMP cancers (RKO, SW48, and FET). Expression levels of BLM and RECQL4mRNA were
higher than those of RECQL, RECQL5, and WRN, regardless of molecular subgroup. (B) RECQ helicase mRNA expression compared to
normal colonic mucosa for CRC cell lines. RECQL4 expression is significantly higher in the cell lines compared to the normal colonic
mucosa (P = .002), whereas RECQL expression is significantly decreased (P < .002). Asterisks indicate statistical significance between
the average expression of the indicated helicase in CRC cell line compared to normal colonic mucosa. (C) RECQ helicase Western blot
results for CRC cell lines. PCNA and actin were both run as normalization controls in light of the known correlation of RECQ helicase
expression with the phase of the cell cycle.
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camptothecin derivatives such as irinotecan [16]. The loss of function
of three of the RECQ helicases, WRN, BLM, and RECQL4, results
in human syndromes characterized by a predisposition to cancer,
including CRC [33]. In addition, in vitro studies demonstrate that
these helicases are important in protecting genomic DNA from
genotoxic stress [15,18,24,34–37]. Therefore, we postulated that the
expression of the RECQ helicases is altered in CRC and that the
aberrant expression of these RECQ helicases may have a role in CRC
pathogenesis and in mediating the response of CRC cells to DNA-
damaging chemotherapeutic agents. Our results confirm that the
expression of RECQ helicases in primary CRC tumors is altered com-
pared to normal colonic mucosa. It is plausible that these changes may
be biologically relevant in light of the fact that most RECQ helicases
act in protein complexes and even small changes in expression level
could disrupt the stoichiometry of these complexes and their func-
tion. However, the biologic significance of these changes has yet to be
determined. Our current findings support conducting further studies
of these helicases to determine if they could be predictive biomarkers
or therapeutic targets in CRC.
Our results are consistent with previous findings that RECQL5
may have tumor suppressor effects in CRC [18,19]. We found that
RECQL and RECQL5 are expressed at statistically significant de-
creased levels in CRC when compared to matched normal colonic
mucosa (Figure 2). Although loss of function of RECQL and RECQL5
have not been clearly linked to human disease, there is evidence from
studies of mouse models as well as in vitro systems that loss of function
of these helicases would likely lead to disease given their role in the
maintenance of genomic stability [35,36,38–41]. RECQL5 is impli-
cated in DNA replication, transcription, and repair processes, and
RECQL5 deficiency is thought to contribute to genomic instability
[18,42]. Our data also show that MSI tumors uniformly have decreased
RECQL and RECQL5 expression (Table 2). These data suggest that
RECQL5 and RECQLmay have a role in mediating the degree of MSI
seen in MSI CRC warranting further investigation. Furthermore,
RECQL5-deficient ApcMin/wtmice have been shown to have an increase
in the incidence of tumors formed in the colon. As RECQL5 is highly
conserved between mice and humans, these results are consistent with
a role for RECQL5 as a tumor suppressor in human CRC [19]. Our
data establish the overall decreased expression of both RECQL and
RECQL5 in CRCs and are consistent with previous studies suggesting
that a decrease in RECQL5 expression in tumors would contribute to
the pathogenesis of CRC [18,19,36,37].
We also found that grouping CRC tumors by RECQL5 expression
status (high or low) results in two classes of CRC that are distinct
not only in their expression of RECQL5 but also in their expression
of WRN and RECQL (Figure 3). RECQL5 low (tumor < normal)
CRCs tend to also have lowWRN and RECQL expression. These data
suggest that there may be a biologic link among these three RECQ
helicases. Recently, it has been shown that RECQL5 is important for
cell survival after treatment with camptothecin, a topoisomerase inhibi-
tor [20,42]. Therefore, tumors with decreased expression of RECQL5
compared to normal colonic mucosa, with similarly decreased expres-
sion of WRN and RECQL, may represent a population of cells that are
particularly susceptible to topoisomerase I inhibitors such as irinotecan.
Further studies will help provide insight into this possibility.
In contrast to RECQL and RECQL5, we found that RECQL4 and
BLM expression are significantly increased in CRCs when compared
to matched normal colonic mucosa (Figure 2). An increase in the
expression of these two RECQ helicases may confer a survival advan-
tage to CRC cells and thereby contribute to the pathogenesis of
CRC. RECQL4 and BLM have been shown to have coordinated
activities and to cooperate in repairing DNA damage caused by ioniz-
ing radiation [24]. Our data are consistent with the possibility that
increased expression of BLM and RECQL4 promote the ability of
CRC cells to tolerate genotoxic stress. Functional studies are now
needed to assess this possibility.
We found increased expression of BLM in primary CRCs despite
its role as a tumor suppressor gene in Bloom syndrome and mouse
intestinal cancer [43,44]. Increased BLM expression in established
CRCs may provide a survival advantage for tumor cells, as it has
been shown that BLM can facilitate telomere replication [45,46].
BLM has been co-localized with POT1, TRF1, and TRF2 (proteins
that regulate telomere stability and length) in telomerase-deficient,
alternative lengthening of telomeres–positive cells. When BLM is
depleted in these cells, rapid telomere shortening was shown to occur
[45,47]. Given previous data showing that loss of BLM leads to
increased susceptibility of cells to killing with DNA-damaging agents
[23,34], CRCs that showed an increase in BLM expression compared
to normal colonic mucosa may be a subset of cancers that have
decreased sensitivity to DNA-damaging agents. Our data showing
that CIMP CRCs all have high (tumor > normal) BLM expression
may have implications with regard to the effect of chemotherapy on
CIMP CRCs compared to non-CIMP CRCs.
We also observed significant overexpression of RECQL4 in the
CRCs. Recent studies show that RECQL4 expression is also increased
in metastatic prostate cancer cell lines [48] as well as in sporadic osteo-
blastomas [49]. Loss of RECQL4 activity leads to an accumulation
of double-strand breaks, and knockdown of RECQL4 decreases both
tumorigenicity and invasiveness [48]. Therefore, increased expression
of RECQL4 may likewise be important in the pathogenesis of CRC,
conferring a survival advantage to the tumor. The data show that
BLM and RECQL4 are the only two RECQ helicases that have
increased expression. This is consistent with the co-localization of
RECQL4 and BLM during S-phase and their reported coordinated
activity [24]. Consistent with previous cell culture studies, our IHC
studies show that BLM and RECQL4 are indeed localized to the
nucleus (Figure 4). The expression of both BLM and RECQL4
widely range in fold change values, making them good candidates to
investigate for a role as predictive biomarkers in CRC.
Our studies showing abnormal expression of the RECQ helicases
in CRC suggest that the RECQ helicase genes may also be targets
for mutations. Therefore, as an adjunct, we assessed the status of
reported RECQ helicase mutations in CRCs in The Cancer Genome
Atlas (TCGA) database (cancergenome.nih.gov/; 20/224 cases) and
determined the predicted functional consequence of these mutations
(Tables W2–W5). We found that there are no reported mutations in
RECQL4, whereas there are reported mutations in BLM (4.5%),WRN
(4.0%), RECQL (1.8%), and RECQL5 (2.7%). Of the reported muta-
tions, approximately half are predicted to disrupt the function of the
gene. Thus, mutational inactivation of the RECQ helicases appears
to be a second mechanism through which potential tumor suppressor
functions of the RECQ helicases may be disrupted. Furthermore, the
lack of reported mutations in RECQL4 and the increased expression
of RECQL4 seen in CRCs suggest that this enzyme may be important
for tumorigenesis.
Potential mechanisms that control RECQ helicase expression
include epigenetic alterations, such as promoter methylation. Our
results show that aberrant promoter methylation of RECQL5 occurs
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in 14% of CRC tumors, suggesting that promoter methylation is
responsible for the transcriptional repression of RECQL5 of only a
small subset of CRCs. However, aberrant DNA methylation does
not appear to be the mechanism responsible for the down-regulation
of RECQL in CRCs, as we did not detect RECQL promoter methyla-
tion in CRCs. Other possible regulatory mechanisms for RECQ
helicases include alterations in transcription factors that enhance or
suppress gene expression and post-transcriptional processing of the
mRNA. There is evidence that RECQL5 is regulated in part by tran-
scription factor binding with a zinc-binding motif, which is highly
conserved among RECQ helicases [50]. There are also data showing
that RECQL5 interacts with RAD51 and that this interaction is
critical for specific RECQL5 function [51]. Furthermore, E2F binding
sites have been identified in RECQ helicase promoters to which both
E2F and Rb can bind and recruit an Rb family repressor complex [52].
The precise mechanism by which the RECQ helicases are regulated is
not fully understood; however, it is clear that this family of proteins
have altered expression in CRCs.
An important technical issue related to our studies is the discrepancy
we observed between the mRNA and protein expression of certain
RECQ helicases in the primary tumors. In our hands, IHC stains
for RECQ expression proved to be less precise in the quantitation of
RECQ expression differences compared to qRT-PCR, with many of
the Allred scores clustering at high levels for RecQL, RecQL4, and
BLM. This is likely because of the more precise quantitative nature
of the qRT-PCR assay compared to the more qualitative nature of
IHC. The lack of correlation inWRN IHC when compared to mRNA
expression in primary tissues was less surprising, as this was consistent
with WRN protein expression compared to mRNA expression in CRC
cell lines assayed by Western blot analysis. The data suggest thatWRN
mRNA levels indeed correlate poorly with protein levels. The differ-
ences seen in expression of RECQL5 in tumor compared to normal
colonic mucosa were consistent at both the mRNA and protein levels,
suggesting that these differences are the most robust and the results
from the RT-PCR assays are comparable to the IHC studies.
In conclusion, we have shown that there are significant differences
among CRCs with regard to the expression of the RecQ helicases as well
as differences in the expression of RecQ helicases between CRCs and
normal colonic tissues. On the basis of the known function of these
helicases, the altered expression of RECQL, RECQL5, RECQL4, and
BLM may affect the formation of CRC as well as the response of CRCs
to chemotherapy. We also observed characteristic expression patterns
of RECQ helicases in the different molecular subtypes of CRC, suggest-
ing that the expression of these DNA repair enzymes may prove to help
classify tumor behavior with regard to response to therapy. The studies
presented here establish the altered expression profile of RECQ helicases
in primary CRCs and provide a strong rationale for further studies of
these helicases as predictive biomarkers or therapeutic targets in CRC.
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Table W1. Probe and Primer Sequences Used in CIMP Analyses of the Colorectal Tumors Using Methylight according to the Protocol Published by Weisenberger et al..
Gene Probe Forward Primer Reverse Primer
Calcium channel, voltage-dependent,
alpha 1G subunit
6FAM-AAATAACGCCGAATC
CGACAACCGA-BHQ-1
TTTTTTCGTTTCGCGTTTAGGT CTCGAAACGACTTCGCCG
Insulin-like growth factor 2 (somatomedin A) 6FAM-CCCTCTACCGTCGCG
AACCCGA-BHQ-1
GAGCGGTTTCGGTGTCGTTA CCAACTCGATTTAAACCGACG
Neurogenin 1 6FAM-CGATAACGACCTCCC
GCGAACATAAA-BHQ-1
CGTGTAGCGTTCGGGTATTTGTA CGATAATTACGAACACACTCCGAAT
Runt-related transcription factor 3 6FAM-CGCACGAACTCGCC
TACGTAATCCG-BHQ-1
CGTTCGATGGTGGACGTGT GACGAACAACGTCTTATTACAACGC
Suppressor of cytokine signaling 1 6FAM-ACAATTCCGCTAAC
GACTATCGCGCA-BHQ-1
GCGTCGAGTTCGTGGGTATTT CCGAAACCATCTTCACGCTAA
ALU 6FAM-CCTACCTTAACCTCCC-
MGBNFQ
GGTTAGGTATAGTGGTTTATATT
TGTAATTTTAGTA
ATTAACTAAACTAATCTTAAACTCCT
AACCTCA
All sequences are provided 5′ to 3′.
Figure W1. Fold change of RECQ helicase mRNA expression with-
out normalization for proliferation using PCNA mRNA expression
(CRC/normal colon). Solid horizontal lines indicate the median fold
change for each RECQ helicase. The dashed horizontal line indi-
cates a fold change level of 1, where the expression level of the
RECQhelicase in the tumor is equal to the expression level in normal
colonic mucosa. WRN (P = .0259), BLM (P < .0001), RECQL (P <
.0183), and RECQL4 (P < .001) expression levels are significantly
increased in tumor compared to normal mucosa. There is no sig-
nificant difference in RECQL5mRNA expression in tumor compared
to normal colonic mucosa (P = .182). Asterisks indicate statistical
significance in the fold change compared to the theoretical mean
of 1 for the indicated helicases.
Figure W2. ROC curves for RECQ helicase expression in CRC and normal colonic mucosa. The area under the curve and 95% confi-
dence intervals for each ROC analysis are given as follows: WRN, 0.7136 (0.6067-0.8205); BLM, 0.6101 (0.4940-0.7262); RECQL, 0.6994
(0.5920-0.8069); RECQL4 (0.5103-0.7402); RECQL5 (0.6236-0.8329). Dashed line is the line of identity.
Figure W3. Analysis of RECQ helicase expression by CRC stage. (A) RECQ helicase mRNA expression. There is a significant difference
in fold change of WRN expression in the CRCs compared to normal mucosa by stage (P = .0498); however, after all-pairwise post-hoc
comparisons, there was not enough power to detect differences among the stages. The highest median expression is seen in stage II
CRC. Higher expression levels of WRN in stage II compared to lower expression levels of WRN in the other tumor stages (compared to
matched normal mucosa) can be appreciated. However, no statistical significance is seen in the expression of BLM (P = .2193), RECQL4
(P = .4077), RECQL (P = .5992), or RECQL5 (P = .3889) in the CRCs compared to matched normal tissue in any of the stages. (B) RECQ
helicase IHC. On the basis of Allred scores, there is no statistically significant difference in expression of the RECQ helicases in CRCs across
stages, WRN (P = .5709), BLM (P = .3644), RECQL4 (P = .5451), RECQL (P = .1922), or RECQL5 (P = .5604).
Table W4. Somatic RECQL Mutations Identified by TCGA in CRCs and Their Predicted Impact.
RECQL AA
Mutation Mutation Type Mutation Assessor Polyphen-2 Exome Variant
A248T Missense Neutral Benign No
N397K Missense Medium Probably damaging No
S568L Missense Medium Probably damaging No
V41* Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
*Signifies deletion (caused by the frameshift mutation).
Table W5. Somatic RECQL5Mutations Identified by TCGA in CRCs and Their Predicted Impact.
RecQL5 AA
Mutation Mutation Type Mutation Assessor Polyphen-2 Exome Variant
E573D Missense Neutral Benign No
L556I Missense Low Benign No
C832Y Missense Low Benign No
E980K Missense Medium Possibly damaging No
G71C Missense Medium Probably damaging No
T316I Missense High Probably damaging No
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
Table W2. Somatic BLM Mutations Identified by TCGA in CRCs and Their Predicted Impact.
BLM AA
Mutation Mutation Type Mutation Assessor PolyPhen-2 Exome Variant
L647I Missense Low Benign No
A964T Missense Low Benign No
F1087C Missense Low Benign No
S1252F Missense Low Possibly damaging No
S147Y Missense Medium Probably damaging No
Y784C Missense Medium Possibly damaging No
R1144I Missense Medium Possibly damaging No
A703V Missense High Probably damaging No
Y764C Missense High Probably damaging No
HPfs (3518) Frameshift – – –
HPfs (3811) Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
Table W3. Somatic WRN Mutations Identified by TCGA in CRCs and Their Predicted Impact.
BLM AA
Mutation Mutation Type Mutation Assessor PolyPhen-2 Exome Variant
L647I Missense Low Benign No
A964T Missense Low Benign No
F1087C Missense Low Benign No
S1252F Missense Low Possibly damaging No
S147Y Missense Medium Probably damaging No
Y784C Missense Medium Possibly damaging No
R1144I Missense Medium Possibly damaging No
A703V Missense High Probably damaging No
Y764C Missense High Probably damaging No
HPfs (3518) Frameshift – – –
HPfs (3811) Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
